Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas

Prof Marek Trněný - Charles University, Prague, Czechia
Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas ( Prof Marek Trněný - Charles University, Prague, Czechia )
18 Jun 2026

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival

Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival ( Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )
18 Jun 2026

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA
Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )
1 Jun 2026

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma

Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma ( Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2026

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA
Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment ( Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA )
31 May 2026

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas

Dr Georg Lenz - University Hospital Münster, Münster, Germany
Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas ( Dr Georg Lenz - University Hospital Münster, Münster, Germany )
30 May 2026

Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma

Dr Konstantinos Christofyllakis - Saarland University, Saarbrücken, Germany
Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma ( Dr Konstantinos Christofyllakis - Saarland University, Saarbrücken, Germany )
30 Mar 2026

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma

Dr Lorenzo Falchi - Memorial Sloan Kettering Cancer Center, New York, USA
Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma ( Dr Lorenzo Falchi - Memorial Sloan Kettering Cancer Center, New York, USA )
24 Feb 2026

Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies

Dr Thomas Kuczmarski - Fred Hutchinson Cancer Center, Seattle, USA
Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies ( Dr Thomas Kuczmarski - Fred Hutchinson Cancer Center, Seattle, USA )
5 Feb 2026

Extreme heat exposure around diagnosis is linked to higher mortality in multiple myeloma

Dr Thomas Kuczmarski - Fred Hutchinson Cancer Center, Seattle, USA
Extreme heat exposure around diagnosis is linked to higher mortality in multiple myeloma ( Dr Thomas Kuczmarski - Fred Hutchinson Cancer Center, Seattle, USA )
5 Feb 2026

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes following transplantation

Dr Antonio Jimenez Jimenez - Sylvester Comprehensive Cancer Center, Miami, USA
Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes following transplantation ( Dr Antonio Jimenez Jimenez - Sylvester Comprehensive Cancer Center, Miami, USA )
15 Jan 2026

MS-553 shows promise in treating chronic lymphocytic leukaemia

Prof Jennifer Woyach - The Ohio State University, Columbus, USA
MS-553 shows promise in treating chronic lymphocytic leukaemia ( Prof Jennifer Woyach - The Ohio State University, Columbus, USA )
15 Jan 2026